雖然這篇vertis-cv鄉民發文沒有被收入到精華區:在vertis-cv這個話題中,我們另外找到其它相關的精選爆讚文章
[爆卦]vertis-cv是什麼?優點缺點精華區懶人包
你可能也想看看
搜尋相關網站
-
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#1Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
et al.,; for the VERTIS CV Investigators.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#2VERTIS-CV | Circulation - AHA Journals
The 8246 patients enrolled in VERTIS-CV were at least 40 years of age (mean age 64 years), and all had T2D with established atherosclerotic ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#3Cardiovascular Outcomes Following Ertugliflozin Treatment in ...
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004) ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#4Evaluation of Ertugliflozin Efficacy and Safety Cardiovascular ...
The VERTIS CV trial showed that ertugliflozin is noninferior for reducing CV events in patients with T2DM and established CVD.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#5Cardiovascular Outcomes with Ertugliflozin in Type ... - PubMed
由 CP Cannon 著作 · 2020 · 被引用 468 次 — VERTIS CV Investigators: Jose Maria Pozzi, Laura Maffei, Lucrecia Nardone, Horacio Sessa, Daniela Garcia Brasca, Diego Aizenberg, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#6VERTIS CV: Ertugliflozin Meets Noninferiority Endpoint but ...
A large cardiovascular outcomes trial with ertugliflozin (Steglatro; Merck Sharp & Dohme), another of the sodium-glucose cotransporter 2 (SGLT2) ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#7Design and baseline characteristics of the eValuation of ...
The VERTIS cardiovascular (CV) outcomes trial (NCT01986881) has a primary objective to demonstrate non-inferiority of ertugliflozin versus placebo on major ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#8Effects of ertugliflozin on kidney composite outcomes, renal ...
The kidney composite outcome in VERTIS CV (reported previously) was time to first event of doubling of serum creatinine from baseline, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#9VERTIS-CV: Late-Comer Ertugliflozin Shows HF Benefit Only ...
VERTIS -CV (Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease) enrolled ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#10Efficacy and safety of ertugliflozin in patients with type 2 ...
VERTIS CV was the cardiovascular outcome study for ertugliflozin. Patients were randomly assigned to placebo, or ertugliflozin 5 mg or 15 mg ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#11Do VERTIS-CV trial results question a class-effect of ...
VERTIS -CV, a company-sponsored, multicentre, double-blind, event-driven, non-inferiority trial, investigated the cardiovascular (CV) safety ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#12SGLT2抑制劑Ertugliflozin無法改善心血管疾病與腎病變風險
VERTIS(Evaluation of Ertugliflozin EffIcacy and Safety Cardiovascular ... 在4月30日的財報會議上,默克藥廠表示,VERTIS CV的研究結果 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#13VERTIS-CV,Circulation - X-MOL
VERTIS -CV suggests that patients with T2D and albuminuria are particularly likely to benefit from HF risk reduction with an SGLT2 inhibitor: ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#14VERTIS CV: Ertugliflozin Falls Short of SGLT2s on CV ...
VERTIS CV : Ertugliflozin Falls Short of SGLT2s on CV Outcomes, Despite Promise in Heart Failure · the HR for the composite of CV death and HHF ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#15(PDF) Design and baseline characteristics of the eValuation of ...
The VERTIS cardiovascular (CV) outcomes trial (NCT01986881) has a primary objective to demonstrate non-inferiority of ertugliflozin versus placebo on major ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#16The VERTIS CV Trial - University of Tennessee Health ...
The VERTIS CV Trial. Cardiovascular Outcomes Following Ertugliflozin. Treatment in Patients with Type 2 Diabetes Mellitus.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#17VERTIS CV: new insights in heart failure understanding - EASD
VERTIS CV : new insights in heart failure understanding'. Session: Building the latest scientific and clinical understanding for the treatment of patients ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#18VERTIS-CV: Long-Awaited Cardiovascular Efficacy and Safety ...
VERTIS -CV trial suggests that ertugliflozin is not superior to placebo in reducing MACE but may reduce hospitalization for heart failure.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#19Metformin use may not influence SGLT2 inhibitor effect
Post-hoc analysis of the VERTIS-CV trial indicates that the cardiovascular effects of ertugliflozin are unaffected by whether people are ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#20Association of SGLT2 Inhibitors With Cardiovascular and ...
The VERTIS CV trial assessed the effects of ertugliflozin vs placebo in patients with T2D and prevalent ASCVD. Our study results represent ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#21VERTIS CV: Ertugliflozin reduces HF events in diabetes, ASCVD
As Healio previously reported, in the main results of VERTIS CV, ... ASCVD had similar risk for CV events at 3.5 years whether assigned.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#22VERTIS-CV | Physician's Weekly
In this issue of Circulation, Cosentino and colleagues1 report the results of prespecified analyses from the VERTIS-CV trial (Evaluation of ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#23VERTIS-CV: Ertugliflozin's CV outcomes trial confirms SGLT2i ...
This negated the statistical validity of the only statistically significant treatment difference between ertugliflozin and placebo seen in ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#24新藥介紹:Ertugliflozin (Steglatro ) - 國泰綜合醫院
VERTIS -CV Investigators. Design and baseline characteristics of the eValuation of. ERTugliflozin effIcacy and Safety. CardioVascular outcomes trial (VERTIS-.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#25VERTIS CV | 糖尿病トライアルデータベース - EBM-Library
VERTIS CV ... Frederich R, Gallo S, Cosentino F, et al.; VERTIS CV Investigators: Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#26PRESPECIFIED ANALYSES FROM VERTIS CV - Kidney ...
In VERTIS CV, patients with T2DM and atherosclerotic CV disease were randomized to placebo, ertugliflozin 5 mg or ertugliflozin 15 mg on top of standard of ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#27Matthew Budoff, ENDO 2021: Findings from a Substudy of the ...
What has the Phase 3 VERTIS CV trial taught us about the cardiovascular safety of ertugliflozin compared with other sodium-glucose ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#28what is the VERdict from the VERTIS-CV trial? - Taylor and ...
The VERTIS-CV trial reaffirms the reduction in heart failure hospitalizations as a likely class effect of SGLT-2 inhibitors. While the trial ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#29Generalizability of sodium-glucose co-transporter-2 inhibitors ...
TIMI 58, EMPA-REG OUTCOME, and VERTIS-CV among unselected patients with type 2 diabetes. Methods: This meta-analysis was registered in PROSPERO ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#30Effect of ertugliflozin on initial egfr decline and chronic slope
Ertugliflozin and slope of chronic egfr prespecified analyses from the randomized vertis cv trial. DZI Cherney, F Cosentino, S Dagogo-Jack, DK McGuire, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#31Merck and Pfizer's SGLT2 Inhibitor STEGLATRO ...
VERTIS CV enrolled 8,246 adults (40 years of age or older) with type 2 diabetes and atherosclerotic CV disease, including patients 65 years of ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#32Cardiovascular outcome trials for diabetes drugs Canagliflozin ...
The VERTIS CV trial with ertugliflozin was disappointing as there was no difference in MACE comparing ertugliflozin and placebo.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#33Investigators will review latest data from VERTIS-CV trial of ...
Detailed findings from the VERTIS-CV trial looking at the safety and efficacy of the SGLT2 inhibitor ertugliflozin will be presented by a ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#34AT2D VERTIS-CV module | ACROSS T2D - Boehringer ...
Whats new Fallback image. AT2D VERTIS-CV module. Whats new Webp. across t2d - thumbnail - vertis cv (sc-crp-08542).webp. Whats New Date. May 2021. Sub Title.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#35VERTIS-CV (Ertugliflozin CV Outcomes Trial) - LinkedIn
VERTIS -CV (Ertugliflozin CV Outcomes Trial): Are The Benefits Of SGLT2 Inhibitors A Class Effect? · Objective · Declarations of interest · Trial ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#36UCLA Previously Published Works - eScholarship
The VERTIS (eValuation of ERTU effIcacy and Safety) CV study evaluated ... This was an 18-week VERTIS CV sub-study in patients with T2DM and.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#37Merck and Pfizer's Steglatro meets primary goal in VERTIS CV ...
Merck (MSD) and Pfizer have reported that the Phase III VERTIS cardiovascular (CV) outcomes clinical trial of Steglatro (ertugliflozin) met its ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#38Type 2 | Diabetes Mellitus ) ( TX11250 ) - CenterWatch
... Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#39SGLT2i reduces HF hospitalizations in T2DM patients with ...
The VERTIS CV trial was a multicenter, randomized, double-blind, placebo-controlled, event-driven trial in T2DM patients with ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#40Vertis-CV-Studie: Ertugliflozin vs. Placebo - Deutsches Ärzteblatt
Die Ergebnisse der Phase-III-Studie VERTIS CV liegen nun vor: Der SGLT2-Hemmer Ertugliflozin, der in Deutschland unter dem Handelsnamen STEGLUJAN® als ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#41design and baseline characteristics of the evaluation ... - JACC
The VERTIS cardiovascular (CV) outcomes trial (NCT01986881) has a primary ... Pbo on time to: 1) the composite endpoint of CV death or ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#42what is the VERdict from the VERTIS-CV trial? - Figshare
This article addresses the Evaluation of Ertugliflozin Efficacy and Safety Cardiovascular Outcomes (VERTIS-CV) trial, its background, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#43Efficacy of Ertugliflozin on Heart Failure: the VERTIS CV Trial
EMA 2021 February. February 2021. Abstract 12: Efficacy of Ertugliflozin on Heart Failure: the VERTIS CV Trial. EMA 2021 February 28 Chapters ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#44Glycemic efficacy and safety of the SGLT2 inhibitor ...
and safety of ertugliflozin in patients in the VERTIS CV cardiovascular outcome trial with chronic kidney disease. (CKD) stage 3.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#45Interpreting the results of the VERTIS-CV trial - Meta.org
Interpreting the results of the VERTIS-CV trial: Is this the end of the "class effect" perspective? Journal of Diabetes.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#46MSD/Pfizer's diabetes drug Steglatro hits goal in CV outcomes ...
MSD and Pfizer have unveiled data from the Phase III VERTIS CV cardiovascular (CV) outcomes trial which add further evidence on the safety ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#47No 'plausible biological or pharmacological explanation' for ...
The “surprising and unexpected” outcome from the VERTIS-CV trial will be discussed at the next DPC Summer Forum webinar.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#48Ο χρήστης Patrick Holmes στο Twitter: "1/4 #ADA2020 ...
1/4 #ADA2020 VERTIS-CV Trial design and additional information of background CV and glucose lowering therapy. While we already know this trial failed to ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#49Vertis CV reforça a importância dos iSGLT2 na IC e na ...
O Vertis CV – o estudo de outcome cardiovascular da ertuglifozina e o 4.º publicado dentro desta classe farmacológica – incluiu 8246 doentes ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#50Merck and Pfizer's SGLT2 Inhibitor STEGLATROTM ...
Merck and Pfizer's SGLT2 Inhibitor STEGLATROTM (ertugliflozin) Meets Primary Endpoint in VERTIS CV Trial for Patients with Type 2 Diabetes ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#51Étude VERTIS-CV : ertugliflozine chez les patients DT2 ayant ...
Les résultats de l'étude VERTIS-CV ont été présentés à l'EASD, avec des résultats complémentaires par rapport à ceux diffusés à l'ADA en ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#52Christopher Cannon, ADA 2020: Results of the Phase III ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#53Study provides additional support for use of new class of ...
VERTIS -CV assessed the drug's cardiovascular safety. Among patients with type 2 diabetes and atherosclerotic cardiovascular disease, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#54Read all Latest Updates on and about vertis cv trial - Medical ...
Get Latest News, Breaking News about vertis cv trial. Stay connected to all updated on vertis cv trial.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#55"VERTIS-CV 연구, 통계적 유의성 못미쳤지만 계열효과 의심 ...
MSD의 SGLT-2억제제 '스테글라트로(성분명 에르투글리플로진)'가 심혈관 임상시험(CVOT)인 VERTIS-CV 연구에서 심혈관 혜택 입증에 실패하며 기대에 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#56VERTIS CV highlights CV safety of ertugliflozin in T2D - MIMS ...
Patients with type 2 diabetes (T2D) and established atherosclerotic cardiovascular disease (ASCVD) do not have a higher risk of major ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#57Merck and Pfizer's SGLT2 Inhibitor STEGLATRO TM ...
Merck and Pfizer's SGLT2 Inhibitor STEGLATRO Meets Primary Endpoint in VERTIS CV Trial for Patients with Type2 Diabetes and Atherosclerotic ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#58American Society of Nephrology | Kidney Week - Abstract ...
Effect of Ertugliflozin on Initial eGFR Decline and Chronic Slope: Analyses from the VERTIS CV Trial. Session Information.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#59SGLT2 inhibitors and cardiovascular outcomes in type 2 ...
SGLT2 inhibitors and cardiovascular outcomes in type 2 diabetes: VERTIS CV trial ... Dr Kevin Fernando summarises results from the cardiovascular ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#60Type 2 Diabetes Mellitus: Cardiovascular Outcome Trials ...
VERTIS -CV Estimated completion 2020 Population: T2DM & established CVD; Ertugliflozin 5mg or 15mg po once daily vs placebo added to usual care; 1o endpoint: ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#61VERTIS CV - Magyar Diabetes Társaság
A VERTIS CV vizsgálat (Evaluation of Ertugliflozin Efficacy and Safety Cardiovascular Outcomes Trial) eredményeit az ADA (Amerikai Diabetes Társaság ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#62News Release - American Diabetes Association
Safety Cardiovascular Outcomes Trial (VERTIS CV), the Effect of Sotagliflozin on. Cardiovascular and Renal Events in Patients with Type 2 Diabetes and ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#63Ertugliflozin ed outcome cardiovascolari: lo studio VERTIS-CV
Ertugliflozin ed outcome cardiovascolari: lo studio VERTIS-CV. Punti chiave. Domanda: Quali sono gli effetti cardiovascolari di ertugliflozin, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#64Ertugliflozin Noninferior to Placebo for Cardiovascular Safety ...
Better late than never might be the perfect adage to describe the VERTIS-CV trial—presented on the final day of the American Diabetes ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#65VERTIS-CV: Ertugliflozin Noninferior to Placebo for MACE
Results of the VERTIS-CV trial indicate ertugliflozin could reduce heart failure hospitalizations but did not demonstrate the ability to ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#66Medications That Protect the Heart: New Data on SGLT-2s ...
Results from the VERTIS-CV trial show that SGLT-2 inhibitor Steglatro benefits heart and kidney health; hear expert opinions on SGLT-2 and ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#67VERTIS CV Trial - Journal Club / Scientific Literature Review
VERTIS CV Trial - Journal Club / Scientific Literature Review. Illustration. Tiffany Chan. Researcher. Content Writer ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#68MSD Specialist Diabetes Expert Input Forum VERTIS CV 2020
MSD Specialist Diabetes Expert Input Forum VERTIS CV 2020. Zoungas, S. (Invited speaker). Epidemiology and Preventive Medicine Alfred ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#69Treating type 2 diabetes with ertugliflozin does not increase ...
The VERTIS CV Study tracked the performance of ertugliflozin, a SGLT2 inhibitor typically prescribed to improve glycemic control, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#70Merck and Pfizer's SGLT2 inhibitor STEGLATRO meets ...
“The VERTIS CV results add to the growing body of evidence regarding the clinical profile of ertugliflozin, including its safety in patients ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#71探討SGLT2 抑制劑對於第2 型糖尿病合併慢性腎疾病的影響與 ...
另一項正在進行中的VERTIS-CV (the. Cardiovascular Outcomes Following Ertugliflozin. Treatment in Type 2 Diabetes Mellitus Participants.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#72VERTIS-CV Results 'Disappoint,' Raise More Questions
The neutral MACE results reinforce 2020 ADA standards of care for SGLT2 inhibitors. https://t.co/dOlCM1AU8z #ADA2020 - view on twitter.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#73Corso FAD Studio Vertis CV
Webinar Studio Vertis CV: Nuovi insight sul valore di Ertugliflozin. 18 giugno 2020. Scarica il programma. 7 crediti ECM ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#74艾托格列净在2型糖尿病患者VERTIS CV试验中达到主要终点
中新网上海新闻6月23日电(记者陈静)记者23日获悉,默沙东与辉瑞公司共同公布了VERTIS CV心血管临床试验的III期研究结果,相关研究结果已发表于第80届 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#75Diabetes experts to discuss VERTIS CV trial outcome
Wednesday's webinar will discuss the findings of the VERTIS CV trial which looked at the safety and health benefits of people with type 2 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#76VERTIS CV trial: Evalución de eficacia y seguridad de la ...
VERTIS CV trial: Evalución de eficacia y seguridad de la Ertuglifozina. Las drogas innovadoras para el tratamiento de la diabetes, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#77Ergebnisse der VERTIS-CV-Studie liegen vor - diabetologie ...
VERTIS CV (NCT01986881) ist eine multizentrische prospektive, randomisierte, endpunkt-gesteuerte Placebo-kontrollierte Studie bei Patienten mit ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#78DBaudiovisuais - Webinar Vertis-CV #live #streaming...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#79The study - Medfyle
... VERTIS clinical trial program spans 9 clinical trials with about 13,000 patients in 40 countries; The main goal of the trial was to assess the CV safety ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#80SGLT2 inhibitors decrease cardiovascular death and heart ...
... Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: results of the VERTIS CV Trial.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#81Capital T - Wikipedia
Trim Ademi (Albanian: [tɾiˈm ˈadɛˈmi]; born 29 February 1992), known professionally as ... Nexhmije Pagarusha · Nikola Rokvić · Nikolija · Nikos Vertis ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#82ct.moreover.com/?a=42503981659&p=1pl&v=1&x=fPq9g0N...
沒有這個頁面的資訊。
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#83ITS Sensors and Architectures for Traffic Management and ...
... and cooperative vehicles The emergence of the Connected Vehicle (CV) Program in the ... Road, and Traffic Intelligence Society (VERTIS), now ITS Japan.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#84Plunkett's Advertising & Branding Industry Almanac 2007: The ...
... DIESTE HARMEL & PARTNERS Alcance en tu Buzon; VERTIS COMMUNICATIONS INC ... TIME WARNER INC Alfa Radio; GRUPO RADIO CENTRO SA DE CV Alibaba.com; YAHOO!
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#85Plunkett's Advertising & Branding Industry Almanac 2008: ...
... CRAIN COMMUNICATIONS INC Advertising Inserts; VERTIS COMMUNICATIONS INC AdVisory Board, ... GRUPO RADIO CENTRO SA DE CV Alliance Entertainment Corp; ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#86Best Ajustes Podcasts (2022) - Player FM
N189 - Risco CV e dislipidemia no DM2 - Diretriz SBD 2021 - Maria ... N176 - Estudo de segurança CV: VERTIS e subanálise do DEVOTE (Highlights EASD) - Joana ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#87Hesiodi Ascraei quae extant, Cum Graecis scholiis, Procli, ...
Nec fat certa gradum , viduat aque ' vertice fums Flexipede vertis veftigis ... Aftrææ Fortunam fucceffiffe , alij Astræam in Fortunam mutatam volunt cv .
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#88Dictionarium latino-Graecum: In quo singulae dictiones ac ...
Liu . cv súpor moiche fo , versas , Versura , Versus , Vide ve R- θαι , κατάζειν . Liu . ... Verto , vertis , verti , versum , vertere .
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#89... Iacobi Avgvsti Thvani ... Historiarvm svi temporis ab ...
CI ) 19 CV 1 . ... tú desperatio in gaudiữ vertis , cum cerca rei exequendæ fiducia : obseruacumq.dum murum alacriter pertūdút , strepitú exaltcra muri ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#90Lexicon linguae arabicae - 第 460 頁 - Google 圖書結果
مطرف Centus vertis ومطارف .Coll , Tractus , اطراف .Coll , رق .Vertes opulentiae . H الثراء Duae طر في ال . ... C. V. Viam fecit , profectus est . : . i .
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#91Synopsis Criticorvm Aliorumque Sacrae Scripturae Interpretum ...
cV . TE I Muce am firepulifti , & c.tè tamen femper prædicabimus ' . ... faciei mea ( quô vultus bej . andato pro Ch.Vertis live Vertifti ; nos in figam ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#92Exemplaria poenitentiae, authore Deo, et impoenitentiae, ...
29 1 CV . cione . ris . ... nota in græco dici ab créaose ; & alia pietatis opera frequentando , poter quod Vatablus vertis abfur dis , Syrus info14 . CIV .
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#93Corpus juris canonici emendatum et notis illustratum
... eft pofterior pars capitis undecimi ex prifca vertis effet omnibusinyolútus ... C. V. A communione fufpendantur , qui post pæni . cùm negligens circa se ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?>
vertis-cv 在 コバにゃんチャンネル Youtube 的最佳貼文
vertis-cv 在 大象中醫 Youtube 的最讚貼文
vertis-cv 在 大象中醫 Youtube 的最佳貼文